Multiple Myeloma

Key opinion leaders provide insight on patient considerations when formulating an optimal treatment regimen for multiple myeloma.

Drs Haumschild, Anderson, and Hinojosa explore current MM treatment pathways.

Medical experts discuss treatment options for indolent and aggressive relapse multiple myeloma.

Dr Haumschild opens the discussion with Larry Anderson, MD, PhD, and Gabe Hinojosa, PharmD, BCOP, regarding various states of relapse in multiple myeloma.

Ryan Haumschild, PharmD, MS, MBA, discussed his presentation at the Oncology Pharmacists Connect meeting, taking place June 15 through 17 in Austin, Texas.

A single infusion of ciltacabtagene autoleucel produced a lower risk of death and disease progression, as well as deep and durable responses, in heavily pretreated patients with relapsed/refractory multiple myeloma.

Findings highlight the potential efficacy of combining 2 novel bispecific therapies, teclistamab-cqyv and talquetamab, which target distinct antigens on myeloma cells.

Multiple myeloma treatment selection is critical due to the potential for developing treatment resistance over time to the currently prescribed drugs.

Program Chair Ryan Haumschild, PharmD, MS, MBA, discussed what attendees can look forward to at the inaugural Oncology Pharmacists Connect meeting.

Expert notes significant advances in the treatment of multiple myeloma, large B cell lymphomas, and acute myeloid leukemia, during a presentation at HOPA 2023 Annual Conference.

Since 2014, 10 immunotherapies have been approved by the FDA, including 6 CAR T-cell therapies and 4 BiTE therapies.

In their closing thoughts, Mr Haumschild leads the panel in a discussion regarding treatments on the horizon for patients with relapsed/refractory multiple myeloma.

Toxicity management associated with anti-CD38 drugs is highlighted by a panel of medical experts.

Elranatamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody that may become the next standard of care for multiple myeloma, according to researchers.

Total cost of care for multiple myeloma can be significantly affected by selection of dosing regimen.

Key opinion leaders emphasize the critical role of effective clinical pathways for treatment in multiple myeloma.

Because of CRS and neurologic toxicity risk, the therapy is available through a REMS program.

Idecabtagene vicleucel prolonged progression-free survival by more than 1 year in a difficult-to-treat patient population with relapsed or refractory multiple myeloma.

4-drug treatment regimens could provide optimal care strategies for patients with multiple myeloma.

Experts discuss the results of the IKEMA and CANDOR trials.

Isatuximab and daratumumab offer promising treatment options for previously treated multiple myeloma.

Dr Haumschild leads a discussion surrounding key considerations when using anti-CD38 drugs.

Medical experts emphasize anti-CD38 agent utilization for treatment of patients with multiple myeloma.

The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma.